CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands |
Dec. 31, 2021 |
Dec. 31, 2020 |
| Current assets: |
|
|
| Cash and cash equivalents |
$ 63,458
|
$ 16,455
|
| Marketable securities |
5,993
|
27,804
|
| Accounts receivable - related party |
507
|
|
| Prepaid and other current assets |
1,354
|
1,077
|
| Total current assets |
71,312
|
45,336
|
| Property and equipment, net |
451
|
906
|
| Operating lease right-of-use asset |
3,190
|
1,648
|
| Investment in Angel Pharmaceuticals |
34,266
|
37,225
|
| Other assets |
236
|
414
|
| Total assets |
109,455
|
85,529
|
| Current liabilities: |
|
|
| Accounts payable |
1,565
|
3,467
|
| Operating lease liability |
1,046
|
1,078
|
| Accrued and other liabilities |
7,081
|
7,604
|
| Total current liabilities |
9,692
|
12,149
|
| Operating lease liability |
2,601
|
1,232
|
| Total liabilities |
12,293
|
13,381
|
| Commitments and contingencies (Note 13) |
|
|
| Stockholders' equity: |
|
|
| Preferred stock: $0.0001 par value; 10,000,000 shares authorized at December 31, 2021 and December 31, 2020; 0 shares issued and outstanding at December 31, 2021 and December 31, 2020 |
|
|
| Common stock: $0.0001 par value; 290,000,000 shares authorized at December 31, 2021 and December 31, 2020; 46,553,511 and 28,372,634 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively |
5
|
3
|
| Additional paid-in capital |
361,669
|
295,281
|
| Accumulated other comprehensive (loss) income |
1,869
|
4
|
| Accumulated deficit |
(266,381)
|
(223,140)
|
| Total stockholders' equity |
97,162
|
72,148
|
| Total liabilities and stockholders' equity |
$ 109,455
|
$ 85,529
|